Staidson (Beijing) BioPharmaceuticals Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Wang Chao

Chief Executive Officer (CEO)

CN¥1.7m

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	2.8yrs
Participación del CEO	0.08%
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	4.2yrs

Actualizaciones recientes de la dirección

Recent updates

What Staidson (Beijing) BioPharmaceuticals Co., Ltd.'s (SZSE:300204) 25% Share Price Gain Is Not Telling You

Mar 18

CEO

Wang Chao (41 yo)

2.8yrs

Permanencia

CN¥1,707,100

Compensación

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Zhi Wen Zhou	Chairman	15yrs	CN¥1.28m	1.1% CN¥ 34.1m
Tao Li	Supervisor	13.3yrs	CN¥168.10k	sin datos
Hongshan Zhang	Chairman of Supervisory Board	5.7yrs	CN¥240.00k	0.098% CN¥ 3.0m
Rong Qin Zhang	Non-Independent Director	5.7yrs	CN¥1.70m	0.21% CN¥ 6.4m
Ying Sun	Independent Director	5.7yrs	CN¥136.80k	sin datos
Lianchun Yang	Non-Independent Director	2.8yrs	CN¥1.60m	0.075% CN¥ 2.3m
Li Zhao	Independent Director	2.8yrs	CN¥136.80k	sin datos
Jiajun Zhao	Independent Director	2.8yrs	CN¥136.80k	sin datos
Hong Zheng	Employee Supervisor	2.8yrs	sin datos	0.024% CN¥ 741.7k
Xiaoyan Wang	Director	1.7yrs	sin datos	sin datos

4.2yrs

Permanencia media

58.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 300204 se considera experimentada (4.1 años de antigüedad promedio).

Staidson (Beijing) BioPharmaceuticals Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Staidson (Beijing) BioPharmaceuticals Co., Ltd., Annual General Meeting, Apr 16, 2024

High number of new directors

Recent updates

First quarter 2024 earnings released: CN¥0.01 loss per share (vs CN¥0.10 loss in 1Q 2023)

Staidson (Beijing) BioPharmaceuticals Co., Ltd. to Report Q1, 2024 Results on Apr 25, 2024

Staidson (Beijing) BioPharmaceuticals Co., Ltd., Annual General Meeting, Apr 16, 2024

Full year 2023 earnings released: CN¥0.84 loss per share (vs CN¥0.41 loss in FY 2022)

What Staidson (Beijing) BioPharmaceuticals Co., Ltd.'s (SZSE:300204) 25% Share Price Gain Is Not Telling You

New major risk - Share price stability

Staidson (Beijing) BioPharmaceuticals Co., Ltd. to Report Fiscal Year 2023 Results on Mar 26, 2024

New minor risk - Share price stability

Third quarter 2023 earnings released: CN¥0.068 loss per share (vs CN¥0.15 loss in 3Q 2022)

Second quarter 2023 earnings released: CN¥0.22 loss per share (vs CN¥0.14 loss in 2Q 2022)

Full year 2022 earnings released: CN¥0.41 loss per share (vs CN¥0.29 loss in FY 2021)

Third quarter 2022 earnings released: CN¥0.15 loss per share (vs CN¥0.14 loss in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.14 loss per share (vs CN¥0.094 loss in 2Q 2021)

Full year 2021 earnings: EPS and revenues miss analyst expectations

High number of new directors

Third quarter 2021 earnings released: CN¥0.14 loss per share (vs CN¥0.05 loss in 3Q 2020)

Second quarter 2021 earnings released: CN¥0.094 loss per share (vs CN¥0.11 loss in 2Q 2020)

First quarter 2021 earnings released: CN¥0.04 loss per share (vs CN¥0.05 loss in 1Q 2020)

Staidson (Beijing) BioPharmaceuticals Co., Ltd. to Report Fiscal Year 2020 Results on Apr 20, 2021

New 90-day low: CN¥8.02

New 90-day low: CN¥8.59

New 90-day low: CN¥9.90

Third quarter earnings released

New 90-day low: CN¥10.52

New 90-day low: CN¥10.73

First half earnings released

Staidson (Beijing) BioPharmaceuticals Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020

New 90-day high - CN¥13.02

CEO

Permanencia

Compensación

Miembros de la Junta

Permanencia media

Promedio de edad